<DOC>
	<DOC>NCT01544309</DOC>
	<brief_summary>The purpose of this study is to compare the effect of rosuvastatin and atorvastatin on lipid lowering effect and glucose metabolism in hypercholesterolemia patients with diabetes mellitus.</brief_summary>
	<brief_title>LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1. Hypercholesterolemia patients • Patients who have not achieved the target control levels of LDLC in the "Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2007" 2. Type 2 diabetes patients Patients diagnosed with type 2 diabetes and receiving diet therapy, exercise therapy, or medication Patients who received constant therapy for three months before registration and have no plan for therapy change Patients with kept HbA1c level (Japan Diabetes Society [JDS] level) of less than 7.0% (or, National Glycohemoglobin Standardization Program [NGSP] level of less than 7.4%) within three months before registration Patients receiving or not receiving medication at present 3. Patients giving voluntary written consent to participate in the study 4. Male or female patients at 20 years or older 1. Patients who administered rosuvastatin, atorvastatin or ezetimibe within three month at the registration 2. Patients with severe hypertension (systolic blood pressure [SBP] ≥ 180 mmHg or diastolic blood pressure [DBP] ≥ 110 mmHg) 3. Patients with type 1 diabetes 4. Patients judged to have familial hypercholesterolemia 5. Patients with a serum triglyceride level of ≥ 400 mg/dL 6. Patients who had the onset of cardiovascular or cerebrovascular disease within three months 7. Patients with serious heart failure (NYHA classification III IV) 8. Patients with a history of hypersensitivity to statins 9. Patients with a history of druginduced myopathy 10. Patients with severe complication of diabetes 11. Patients receiving insulin 12. Patients with serious liver or kidney disease 13. Patients with serious concurrent disease such as malignancy, or patients with severely limited lifespan 14. Patients who are or may be pregnant 15. Patients judged by the investigators to be ineligible for participation in the study for any other reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>